
Portable Multiplex Pathogen Detector

R. Rao, S. Visuri, M.T. McBride, D. Matthews

This article was submitted to Twenty First Southern Biomedical Engineering Conference, Washington, DC, September 28-29, 2002

July 15, 2002





DISCLAIMER

This document was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor the University of California nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or the University of California, and shall not be used for advertising or product endorsement purposes.

This is a preprint of a paper intended for publication in a journal or proceedings. Since changes may be made before publication, this preprint is made available with the understanding that it will not be cited or reproduced without the permission of the author.

This work was performed under the auspices of the United States Department of Energy by the University of California, Lawrence Livermore National Laboratory under contract No. W-7405-Eng-48.

This report has been reproduced directly from the best available copy.

Available electronically at http://www.doc.gov/bridge

Available for a processing fee to U.S. Department of Energy
And its contractors in paper from
U.S. Department of Energy
Office of Scientific and Technical Information
P.O. Box 62
Oak Ridge, TN 37831-0062

Telephone: (865) 576-8401 Facsimile: (865) 576-5728 E-mail: reports@adonis.osti.gov

Available for the sale to the public from U.S. Department of Commerce National Technical Information Service 5285 Port Royal Road Springfield, VA 22161 Telephone: (800) 553-6847 Facsimile: (703) 605-6900

E-mail: <u>orders@ntis.fedworld.gov</u>
Online ordering: <u>http://www.ntis.gov/ordering.htm</u>

OR

Lawrence Livermore National Laboratory
Technical Information Department's Digital Library
http://www.llnl.gov/tid/Library.html

PORTABLE MULTIPLEX PATHOGEN DETECTOR

Rupa Rao, ¹ Steve Visuri, ² Mary T. McBride, ² Dennis Matthews. ²

Department of Biomedical Engineering, University of California, Davis ² Medical Technology Program, Lawrence Livermore National Laboratory

ABSTRACT

Tumor marker concentrations in serum provide useful information regarding clinical stage and prognosis of cancer¹ and can thus be used for presymtomatic diagnostic purposes. Currently, detection and identification of soluble analytes in biological fluids is conducted by methods including bioassays, ELISA, PCR, DNA chip or strip tests. While these technologies are generally sensitive and specific, they are time consuming, labor intensive and cannot be multiplexed. Our goal

is to develop a simple, point-of-care, portable, liquid array-based immunoassay device capable of simultaneous detection of a variety of cancer markers.

Here we describe the development of assays for the detection of Serum Prostate Specific Antigen, and Ovalbumin from a single sample. The multiplexed immunoassays utilize polystyrene microbeads. The beads are imbedded with precise ratios of red and orange fluorescent dyes yielding an array of 100 beads, each with a unique spectral address (Figure 1). Each bead can be coated with capture antibodies specific for a given antigen. After antigen capture, secondary antibodies sandwich the bound antigen and are




Figure: 1 Different antibodies on each bead enables deeply multiplexed detection

indirectly labeled by the fluorescent reporter phycoerythrin (PE). Each optically encoded and fluorescently- labeled microbead is then individually interrogated. A red laser excites the dye molecules imbedded inside the bead and classifies the bead to its unique bead set, and a green laser quantifies the assay at the bead surface. This technology has been proven to be comparable to the ELISA in terms of sensitivity and specificity.²

We also describe the laser-based instrumentation used to acquire fluorescent bead images Following the assay, droplets of bead suspension containing a mixture of bead classes were deposited onto filters held in place by a disposable plexiglass device and the resultant arrays viewed under the fluorescent imaging setup. Using the appropriate filter sets to extract the necessary red, orange and green fluorescence from the bead array, digital images were captured to computer with a Pixel CCD camera which were subsequently analyzed using customized digital image processing software.

MATERIALS AND METHODS

REAGENT PREPARATION:

Different sets of carboxylated fluorescent microspheres were obtained from Luminex Corp, Austin, TX. Capture antibodies were covalently coupled to a unique carboxylated bead set (1.25 X 10^6 microspheres in 100 μ L) in accordance with the manufacturer's protocol. The end product is a mixture of several bead classes coated with different target proteins. Rabbit Anti-Ovalbumin, Rabbit Anti-Bacillus Globigii (Bg), Rabbit Anti-MS2 were purchased from Tetracore (Gaithersburg, MD). Monoclonal Antibody to PSA and Rabbit Anti-human PSA were purchased from Biodesign Int. (Saco, Maine). The detector antibody cocktail comprised a mixture of the 3 biotinylated antibodies viz. RaOv, RaMs2, RaBg for the respiratory panel and mAPSA, RaPSA and RaOv for the cancer panel at a final concentration of 3 μ g/ml. Antigen solutions were prepared in PBS, pH 7.4. Bg was obtained from Dugway Providing Ground. MS2 was obtained from ATCC, Ovalbumin was purchased from Sigma and Prostate Specific Antigen (ACT complex and 98% pure) from Biodesign International.

MICROSPHERE ASSAY PROTOCOL:

Bead solution was incubated with 100 μL sample for 30 minutes at ambient temperature. The mixture was vacuum aspirated, washed 2X with 100 μL buffer to remove unbound antigen and resuspended in 100 μL PBS-TBN. 50 μL of the biotinylated antibody solution was added to the bead mixture, and incubated 30 minutes. The mixture was vacuum aspirated, washed to remove excess detector antibody and resuspended in 100 μL PBS-TBN. 50 μL SA-PE was added and the reaction mixture incubated 5 minutes. The mixture was vacuum aspirated, washed, and resuspended in 100 μL PBS-TBN. The beads were then transferred to a plexiglass disposable chamber onto a thin flat filter ready for imaging.

INSTRUMENTATION.

Using appropriate laser filter sets to extract the necessary "red-orange" image pair for classification and a "green" image for reporting the level of attached antibodies, digital images of the bead array are captured following laser excitation using a Pixel CCD camera and processed on a PC.

ACKNOWLEDGEMENTS

This work was performed under the auspices of the U.S. Department of Energy by the University of California, Lawrence Livermore National Laboratory under Contract No.W-7405-Eng-48, with funding from the LDRD Program.

REFERENCES

- 1. Badalament, RA; Drago, JR. (1990) Prostate cancer. Promising advances that may alter survival rates. Postgrad. Med. Apr;87(5):65-7, 70-2
- 2. Bhalgat, MK; Haugland, RP; Pollack, JS; (1998) Green- and red-fluorescent nanospheres for the detection of cell surface receptors by flow cytometry. J. Immunol. Methods. 1998 Oct 1;219(1-2):57-68.
- 3. Pickering, JW; Martins, TB; Schroder, MC; (2002) Comparison of a Multiplex Flow Cytometric Assay with Enzyme-Linked Immunosorbent Assay for Quantitation of Antibodies to Tetanus, Diphtheria, and Haemophilus influenzae Type b. Clin. Diagn. Lab. Immunol. 2002 Jul;9(4):872-6